SuperworthImageneBio price to sales ratio IMA
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 8.7×
- Aug 2024
- 5-year median
- 6.8×
- 5-year range
- 2.5× to 17.0×
- Peer median
- 1.4×
ImageneBio's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Aug 2024, at 8.7×.
On the days it had one over the last 5 years, its median was 6.8×, from 2.5× in Nov 2022 to 17.0× in May 2023.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 8.7× | 4.6× | 9.3× |
| 2023 | 6.8× | 3.3× | 17.0× |
| 2022 | 3.2× | 2.5× | 9.3× |
Against its peers
Companies in Healthcare nearest ImageneBio's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| IMAImageneBio | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 0.9× |
| NEPHNephros | 1.9× |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 0.3× |
| PDEXPro DEX | 2.6× |
| PLXProtalix BioTherapeutics | 2.5× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on ImageneBio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.